Taysha Gene Therapies Inc (NASDAQ: TSHA) flaunted slowness of -0.50% at $3.99, as the Stock market unbolted on Thursday, before settling in for the price of $4.01 at the close. Taking a more long-term approach, TSHA posted a 52-week range of $1.05-$5.51.
The Healthcare sector firm’s twelve-monthly sales growth has been -63.99% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -63.99%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -1.19%. This publicly-traded company’s shares outstanding now amounts to $273.92 million, simultaneously with a float of $224.25 million. The organization now has a market capitalization sitting at $1.09 billion. At the time of writing, stock’s 50-day Moving Average stood at $4.17, while the 200-day Moving Average is $2.74.
Taysha Gene Therapies Inc (TSHA) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Taysha Gene Therapies Inc industry. Taysha Gene Therapies Inc’s current insider ownership accounts for 18.13%, in contrast to 89.57% institutional ownership. Preceding that transaction, on Sep 10 ’25, Company’s President and Head of R&D sold 200,000 for 3.23, making the whole transaction’s value amount to 646,000. This particular insider is now the holder of 1,006,439 in total.
Taysha Gene Therapies Inc (TSHA) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
Taysha Gene Therapies Inc’s EPS decrease for this current 12-month fiscal period is -1.19% and is forecasted to reach -0.45 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -0.58% through the next 5 years, which can be compared against the -63.99% growth it accomplished over the previous five years trading on the market.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Trading Performance Indicators
Let’s observe the current performance indicators for Taysha Gene Therapies Inc (TSHA). It’s Quick Ratio in the last reported quarter now stands at 10.47. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 173.21.
In the same vein, TSHA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.35, a figure that is expected to reach -0.10 in the next quarter, and analysts are predicting that it will be -0.45 at the market close of one year from today.
Technical Analysis of Taysha Gene Therapies Inc (TSHA)
Now, what If we examine the latest scores posted by [Taysha Gene Therapies Inc, TSHA]. During the last 5-days, its volume was lower the volume of 3.87 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 42.91% While, its Average True Range was 39.19.
Raw Stochastic average of Taysha Gene Therapies Inc (TSHA) in the period of the previous 100 days is set at 52.23%, which indicates a major rise in contrast to 34.26% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.36 that was higher than 0.25 volatility it exhibited in the past 100-days period.
